Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant dovitinib in hepatocellular carcinoma prior to local treatment
2011-002445-36Phase 2Active
- Sponsor
- Leiden University Medical Center
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dovitinib in hepatocellular carcinoma (HCC), sponsored by Leiden University Medical Center. Primary endpoint: Toxicity and safety of TKI258 (all grades, and grade 3 or 4 toxicities). Started Aug 2011; status: active.
02
Drugs
dovitinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2011-002445-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002445-36.